KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $1.9 billion.

  • Ionis Pharmaceuticals' Short-term Investments fell 1148.81% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year decrease of 1148.81%. This contributed to the annual value of $2.1 billion for FY2024, which is 640.0% up from last year.
  • As of Q3 2025, Ionis Pharmaceuticals' Short-term Investments stood at $1.9 billion, which was down 1148.81% from $2.0 billion recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Short-term Investments ranged from a high of $2.1 billion in Q3 2024 and a low of $1.2 billion during Q4 2021
  • Over the past 5 years, Ionis Pharmaceuticals' median Short-term Investments value was $1.9 billion (recorded in 2024), while the average stood at $1.8 billion.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Short-term Investments plummeted by 2592.62% in 2021 and then surged by 3729.5% in 2022.
  • Over the past 5 years, Ionis Pharmaceuticals' Short-term Investments (Quarter) stood at $1.2 billion in 2021, then surged by 37.3% to $1.7 billion in 2022, then rose by 12.95% to $1.9 billion in 2023, then grew by 6.4% to $2.1 billion in 2024, then decreased by 7.48% to $1.9 billion in 2025.
  • Its last three reported values are $1.9 billion in Q3 2025, $2.0 billion for Q2 2025, and $1.9 billion during Q1 2025.